Beatrice Benatti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7439131/publications.pdf

Version: 2024-02-01

52	1,129	16	32
papers	citations	h-index	g-index
52	52	52	1571 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Selective DNA Methylation of BDNF Promoter in Bipolar Disorder: Differences Among Patients with BDI and BDII. Neuropsychopharmacology, 2012, 37, 1647-1655.	5.4	166
2	What Happened to Patients With Obsessive Compulsive Disorder During the COVID-19 Pandemic? A Multicentre Report From Tertiary Clinics in Northern Italy. Frontiers in Psychiatry, 2020, 11, 720.	2.6	112
3	Epigenetic modulation of BDNF gene: Differences in DNA methylation between unipolar and bipolar patients. Journal of Affective Disorders, 2014, 166, 330-333.	4.1	85
4	Epigenetic Modulation of BDNF Gene in Patients with Major Depressive Disorder. Biological Psychiatry, 2013, 73, e6-e7.	1.3	79
5	Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: a study on patients with panic disorder, generalized anxiety disorder and obsessive–compulsive disorder. Microbial Biotechnology, 2013, 7, 374-380.	1.7	56
6	Characterizing impulsivity profile in patients with obsessive–compulsive disorder. International Journal of Psychiatry in Clinical Practice, 2014, 18, 156-160.	2.4	56
7	The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: A report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). European Neuropsychopharmacology, 2013, 23, 865-871.	0.7	53
8	Childhood, adolescent and adult age at onset and related clinical correlates in obsessive–compulsive disorder: a report from the International College of Obsessive–Compulsive Spectrum Disorders (ICOCS). International Journal of Psychiatry in Clinical Practice, 2016, 20, 210-217.	2.4	50
9	Mood stabilizers for patients with bipolar disorder: the state of the art. Expert Review of Neurotherapeutics, 2011, 11, 85-99.	2.8	36
10	Parsing the phenotype of obsessive-compulsive tic disorder (OCTD): a multidisciplinary consensus. International Journal of Psychiatry in Clinical Practice, 2017, 21, 156-159.	2.4	30
11	Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). CNS Spectrums, 2018, 23, 59-66.	1.2	30
12	Exploring the role of BDNF DNA methylation and hydroxymethylation in patients with obsessive compulsive disorder. Journal of Psychiatric Research, 2019, 114, 17-23.	3.1	29
13	Regulation of gene transcription in bipolar disorders: Role of DNA methylation in the relationship between prodynorphin and brain derived neurotrophic factor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 82, 314-321.	4.8	26
14	Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive–compulsive disorder?. International Clinical Psychopharmacology, 2016, 31, 347-352.	1.7	23
15	Investigating duration of illness and duration of untreated illness in obsessive compulsive disorder reveals patients remain at length pharmacologically untreated. International Journal of Psychiatry in Clinical Practice, 2019, 23, 311-313.	2.4	20
16	Cigarette smoking in patients with obsessive compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). CNS Spectrums, 2015, 20, 469-473.	1.2	18
17	Reduced duration of untreated illness over time in patients with schizophrenia spectrum, mood and anxiety disorders. Psychiatry and Clinical Neurosciences, 2016, 70, 202-210.	1.8	17
18	Augmentative transcranial direct current stimulation (tDCS) in poor responder depressed patients: a follow-up study. CNS Spectrums, 2014, 19, 347-354.	1.2	16

#	Article	IF	CITATIONS
19	Differences in duration of untreated illness, duration, and severity of illness among clinical phenotypes of obsessive-compulsive disorder. CNS Spectrums, 2015, 20, 474-478.	1.2	16
20	Differentiating multiple vs single lifetime suicide attempters with bipolar disorders: A retrospective study. Comprehensive Psychiatry, 2018, 80, 214-222.	3.1	15
21	Genetic and epigenetic architecture of Obsessive-Compulsive Disorder: In search of possible diagnostic and prognostic biomarkers. Journal of Psychiatric Research, 2021, 137, 554-571.	3.1	15
22	Neuroimaging procedures and related acquisitions in bipolar disorder: state of the art. Rivista Di Psichiatria, 2014, 49, 2-11.	0.6	15
23	Factors characterizing access and latency to first pharmacological treatment in Italian patients with schizophrenia, mood, and anxiety spectrum disorders. International Clinical Psychopharmacology, 2015, 30, 29-35.	1.7	13
24	Clinical features associated with increased severity of illness in tertiary clinic referred patients with obsessive compulsive disorder. International Journal of Psychiatry in Clinical Practice, 2017, 21, 131-136.	2.4	12
25	Polypharmacy as maintenance treatment in bipolar illness: A systematic review. Acta Psychiatrica Scandinavica, 2021, 144, 259-276.	4.5	11
26	Lifetime bipolar disorder comorbidity and related clinical characteristics in patients with primary obsessive compulsive disorder: a report from the International College of Obsessive–Compulsive Spectrum Disorders (ICOCS). CNS Spectrums, 2020, 25, 419-425.	1,2	10
27	Suicidal ideation and suicidal attempts in patients with obsessive-compulsive tic-related disorder vs obsessive-compulsive disorder: results of a multicenter Italian study. CNS Spectrums, 2021, 26, 354-361.	1.2	10
28	A preliminary investigation of Cyberchondria and its correlates in a clinical sample of patients with obsessive–compulsive disorder, anxiety and depressive disorders attending a tertiary psychiatric clinic. International Journal of Psychiatry in Clinical Practice, 2022, 26, 111-122.	2.4	10
29	Efficacy, tolerability, compliance, and quality of life of patients with mood disorders switched from Quetiapine immediate release to extended release. International Clinical Psychopharmacology, 2012, 27, 1.	1.7	9
30	Clinical characteristics and comorbidity associated with female gender in obsessive-compulsive disorder. Journal of Psychiatric Research, 2020, 131, 209-214.	3.1	9
31	The role of gender in a large international OCD sample: A Report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Network. Comprehensive Psychiatry, 2022, 116, 152315.	3.1	9
32	Clinical characterization of Italian suicide attempters with bipolar disorder. CNS Spectrums, 2018, 23, 271-277.	1,2	8
33	Italian patients with more recent onset of Major Depressive Disorder have a shorter duration of untreated illness. International Journal of Clinical Practice, 2017, 71, e12926.	1.7	7
34	Prevalence and correlates of current suicide risk in an international sample of OCD adults: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) network and Obsessive Compulsive and Related Disorders Network (OCRN) of the European College of Neuropsychopharmacology. Journal of Psychiatric Research, 2021, 140, 357-363.	3.1	7
35	Prevalence and disability of comorbid social phobia and obsessive–compulsive disorder in patients with panic disorder and generalized anxiety disorder. International Journal of Psychiatry in Clinical Practice, 2014, 18, 248-254.	2.4	6
36	Does initial use of benzodiazepines delay an adequate pharmacological treatment? A multicentre analysis in patients with psychotic and affective disorders. International Clinical Psychopharmacology, 2018, 33, 140-146.	1.7	6

#	Article	IF	CITATIONS
37	Exploring characteristics associated with first benzodiazepine prescription in patients with affective disorders and related diagnoses. Human Psychopharmacology, 2019, 34, e2695.	1.5	6
38	A 6-month follow-up study on response and relapse rates following an acute trial of repetitive transcranial magnetic stimulation in patients with major depression. CNS Spectrums, 2022, 27, 93-98.	1.2	6
39	Access and latency to first antipsychotic treatment in Italian patients with schizophrenia and other schizophrenic spectrum disorders across different epochs. Human Psychopharmacology, 2016, 31, 113-120.	1.5	5
40	Human induced pluripotent stem cells technology in treatment resistant depression: novel strategies and opportunities to unravel ketamine's fast-acting antidepressant mechanisms. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532096833.	2.7	4
41	Clinical uses of Bupropion in patients with Parkinson's disease and comorbid depressive or neuropsychiatric symptoms: a scoping review. BMC Neurology, 2022, 22, 169.	1.8	4
42	Escitalopram tolerability as mono-versus augmentative therapy in patients with affective disorders: a naturalistic study. Neuropsychiatric Disease and Treatment, 2013, 9, 205.	2.2	3
43	Application of a staging model in patients with obsessive–compulsive disorder: cross-sectional and follow-up results. CNS Spectrums, 2022, 27, 218-224.	1.2	3
44	Italian prescribing patterns in obsessive–compulsive disorder. Human Psychopharmacology, 2017, 32, e2641.	1.5	2
45	Antidepressants in bipolar disorder: Analysis of correlates overall, and in BD-I and BD-II subsamples. Journal of Affective Disorders, 2021, 292, 352-358.	4.1	2
46	Post-partum obsessive-compulsive disorder associated with 9q33.1 deletion. Australian and New Zealand Journal of Psychiatry, 2015, 49, 943-944.	2.3	1
47	Prevalence of Selective Serotonin Reuptake Inhibitor–Related Apathy in Patients With Obsessive Compulsive Disorder. Journal of Clinical Psychopharmacology, 2016, 36, 725-726.	1.4	1
48	Assessing response, remission, and treatment resistance in patients with obsessive–compulsive disorder with and without tic disorders: results from a multicenter study. CNS Spectrums, 2022, 27, 747-753.	1.2	1
49	A new tool to assess duration of untreated illness: Psychopathological Onset and Latency to Treatment Questionnaire (POLT-Q). Rivista Di Psichiatria, 2018, 53, 290-298.	0.6	1
50	Neuroimaging Data in Bipolar Disorder: An Updated View. , 0, , .		0
51	The Use of Transcranial Magnetic Stimulation (TMS) for Obsessive-Compulsive Disorder (OCD)., 2019,, 277-293.		0
52	Psychiatry and psychopathology. , 0, , 147-176.		0